// The wordmark of a company that decided the waiting room was the wrong place to fix chronic disease.
A virtual chronic-care company that treats the part of healthcare nobody bills for - the 8,765 hours a year you spend nowhere near a doctor.
A man in Ohio steps on a connected scale before his coffee. The number travels - not to a folder he will never open, but to a human coach who notices the trend before he does, and to an AI that already has a gentle nudge queued up about last night's takeout. He has not seen a doctor in four months. He is, by any reasonable definition, being cared for. This is Omada Health in 2026: a publicly traded company (Nasdaq: OMDA) that turned the dull stretches between appointments into the main event.
Omada is not a hospital, not an app you forget by February, and not a wellness program that mails you a water bottle. It is a virtual chronic-care platform that stacks behavioral science, connected devices, real clinicians, and a growing roster of AI tools to manage prediabetes, diabetes, hypertension, cholesterol, musculoskeletal pain, weight, and the increasingly crowded world of GLP-1 medications. As of its 2025 numbers, more than 886,000 people were enrolled - up 55% in a single year - across some 2,000 employers, health plans, and pharmacy benefit managers.
Here is the inconvenient arithmetic at the center of chronic disease. A patient with type 2 diabetes might spend a generous two or three hours a year in front of a clinician. That leaves roughly 8,762 hours to make every meal, every walk, every skipped medication, and every 11 p.m. decision entirely alone. The American healthcare system, with admirable consistency, only knows how to charge for the hours it can see.
That is the tension Omada exists to resolve. Chronic conditions are not events; they are weather systems. They do not respond well to being managed in fifteen-minute increments twice a year. And yet billing codes, regulations, and the architecture of the entire system are built around "the visit" - a unit of care that, for chronic needs, is almost charmingly beside the point.
The result is a slow-motion crisis hiding in plain sight: prediabetes that quietly becomes diabetes, blood pressure that creeps, weight that climbs, and costs that follow. Doctors do their best inside their narrow window. The window is simply the wrong size for the problem.
Omada's founders looked at that gap and saw, rather than a tragedy, a category. If the system would not pay attention to the time between visits, someone could build a company that did nothing else.
In 2011, Sean Duffy did the thing that sounds reckless in a commencement speech and prudent only in hindsight: he left Harvard Medical School. His conclusion was that the people he wanted to help - patients drowning in the day-to-day management of chronic illness - needed something the clinic was structurally unable to give them. So he teamed up with Adrian James and Andrew DiMichele, and Omada Health was born out of the design firm IDEO's orbit, which explains a great deal about why the product feels less like a medical portal and more like something a person might actually open twice.
Their bet had three legs. First, that behavior change - not just information - was the active ingredient in managing chronic disease. Second, that you could deliver it remotely, at scale, without losing the human touch. Third, and most contrarian at the time, that employers and health plans would actually pay for prevention, a category notorious for being everyone's favorite idea and nobody's line item.
CO-FOUNDER / CEO
Left Harvard Medical School (and an MBA) to chase the between-visit idea. Now rings opening bells.
CO-FOUNDER
Brought design-thinking pedigree to a problem usually solved with clipboards and waiting rooms.
CO-FOUNDER
The engineering half of the founding equation, building the platform behind the behavior change.
Omada started with a single, focused product - a CDC-recognized diabetes prevention program - and then did the thing that good platforms do: it kept adding rooms to the house. Today a member might be enrolled in one program or several, all stitched into the same experience. The connecting thread is never the condition; it is the method. Behavioral science, connected devices that report home, structured curricula, and a human care team that actually replies.
The original CDC-recognized program, focused on durable behavior change rather than crash results.
Cardiometabolic care with connected glucose meters and blood-pressure cuffs feeding live coaching.
Support for members on semaglutide or tirzepatide - including clinical evaluation, labs, and direct prescribing.
Virtual physical therapy for joints and muscles, exercise therapy paired with human coaching.
Launched in early 2026, folding cholesterol into the same integrated dashboard.
OmadaSpark and Meal Map - AI nutrition tools that grade nutrient quality and skip the calorie guilt.
The GLP-1 move is worth pausing on. As the weight-loss drugs went from miracle headline to insurance nightmare, Omada positioned itself as the support system that makes the medication actually stick - and then went further, moving to prescribe the drugs directly. It is a tidy bit of strategy: be indispensable to the most expensive, most talked-about category in healthcare, then own a piece of the prescription itself.
// From IDEO side-project to Nasdaq ticker
Healthy skepticism is the correct posture toward any company promising to fix chronic disease with an app and good intentions - the graveyard of digital health is full of them. So here are the parts that are harder to wave away. Customer satisfaction above 90%. A three-year average customer retention rate above 90% as of the end of 2024. More than a million members supported since launch. And, the ultimate skeptic's test, a public market willing to write the check.
// Annual revenue, reported & guided (USD millions)
*2026 is the midpoint of company guidance ($312M-$322M). 2024 revenue rose 38% year over year. Bars scaled to the guidance midpoint - which is to say, the chart is optimistic on purpose.
Then there is the company it keeps. Omada is a launch partner for Amazon's Health Condition Programs. It built a direct-to-employer GLP-1 channel with Eli Lilly. It holds relationships with the three leading pharmacy benefit managers - the gatekeepers who processed roughly 80% of prescription claims in 2025. These are not the partnerships of a science project. They are the partnerships of a company the rest of the industry has decided to treat as infrastructure.
For all the talk of AI agents and connected cuffs, Omada's mission is almost old-fashioned: inspire and engage people in lifelong health, one step at a time. The radical part was never the goal. It was the insistence that prevention and continuous care could be a real business - that you could make money doing the unglamorous work of helping someone walk a little more and eat a little better, over years, not weeks.
The culture follows from that. Omada is evidence-first to the point of being slightly nerdy about it, leaning on peer-reviewed research and measurable outcomes rather than vibes and testimonials. In a field where "clinically validated" is often a synonym for "we hope so," that rigor is the moat. It is also, conveniently, what lets the company sell to actuaries.
Chronic disease is not getting smaller, and the clinic is not getting bigger. As GLP-1 drugs reshape weight and metabolic care, as employers hunt for anything that bends the cost curve, and as AI makes continuous coaching cheaper to deliver, the value of a company built entirely around the time between visits only goes up. Omada's bet - placed in 2011, ridiculed as a niche, validated on the Nasdaq - is now starting to look less like a startup thesis and more like where healthcare is headed.
None of this is guaranteed. Public markets are fickle, competitors like Hinge Health, Sword Health, and Teladoc's Livongo are not standing still, and "engagement" remains the hardest word in digital health. But the question Omada asked fifteen years ago - what happens to patients after they leave the room? - is no longer a fringe concern. It is the whole game.
Back in Ohio, the man finishes his coffee. The scale has already done its quiet work. His coach will check in by lunch. His doctor will see the trend at a visit that is still months away, and will, for once, have something to look at other than a single bad day. The waiting room did not change. Omada just decided to stop waiting in it.